GeneHealth - Your precision medicine

Hereditary Spastic Paraplegia 14

Disease Details

Family Health Simplified

Buy Membership

Description: Hereditary spastic paraplegia 14 is a genetic disorder characterized by progressive weakness and spasticity of the lower limbs due to degeneration of the corticospinal tract.
Type: Hereditary spastic paraplegia 14 (HSP14) is transmitted in an autosomal recessive manner.
Signs And Symptoms: Hereditary spastic paraplegia 14 (HSP 14) is a subtype of hereditary spastic paraplegia, which is characterized by progressive stiffness and contraction (spasticity) in the lower limbs. Signs and symptoms of HSP 14 typically include:

1. **Lower limb spasticity**: Stiffness and muscle tightness primarily affecting the legs, leading to difficulty with walking and mobility.
2. **Weakness**: Progressive weakness in the lower limbs.
3. **Hyperreflexia**: Exaggerated reflexes in the legs.
4. **Gait abnormalities**: Difficulty in coordinating walking movements, often leading to a spastic gait.
5. **Bladder disturbances**: Issues with bladder control may occur.
6. **Mild cognitive impairment**: Some forms might present with slight cognitive changes, although this is less common.

The progression and severity of these symptoms can vary widely among different individuals with HSP 14.
Prognosis: Hereditary spastic paraplegia type 14 (HSP-14) is a neurodegenerative disorder characterized primarily by progressive spasticity and weakness of the lower limbs. The prognosis can vary significantly among individuals. Some may experience a relatively mild progression of symptoms, allowing them to maintain mobility with minimal assistance, while others may develop more severe spasticity and weakness, potentially leading to significant disability and reliance on mobility aids. Lifespan is generally not affected, and management focuses on alleviating symptoms and maintaining quality of life.
Onset: Hereditary spastic paraplegia 14 (SPG14) typically has an onset that ranges from childhood to adulthood.
Prevalence: The prevalence of Hereditary Spastic Paraplegia 14 (HSP 14) is not well-documented, making it difficult to provide specific figures. Generally, hereditary spastic paraplegias as a group are considered rare, with estimates suggesting a combined prevalence of around 1 to 9 cases per 100,000 people. Since HSP 14 is just one subtype, its prevalence would be even lower, potentially classified as ultra-rare.
Epidemiology: Hereditary Spastic Paraplegia 14 (HSP 14) is a rare genetic disorder characterized by progressive weakness and spasticity of the lower limbs. The prevalence of hereditary spastic paraplegia as a whole is estimated to be 1.27 to 9.6 per 100,000 individuals, but specific data for HSP 14's prevalence are limited due to its rarity.
Intractability: Hereditary Spastic Paraplegia 14 (SPG14) is considered intractable in the sense that there is currently no cure for the disease. Management focuses on symptomatic treatment to improve quality of life, such as physical therapy to maintain mobility and medication to manage spasticity. Research is ongoing to find more effective treatments.
Disease Severity: Hereditary spastic paraplegia type 14 (SPG14) typically presents as a neurodegenerative disorder with variable severity. The disease is characterized primarily by progressive spasticity, particularly in the lower limbs. The severity can range from mild walking difficulties to severe spasticity leading to significant mobility impairment. Additional symptoms may include muscle weakness, urinary urgency, and in some cases, cognitive impairment or other neurological features. The progression of the disease can also vary among individuals.
Healthcare Professionals: Disease Ontology ID - DOID:0110767
Pathophysiology: Hereditary spastic paraplegia 14 (HSP 14) is a form of hereditary spastic paraplegia, a group of genetic disorders characterized by progressive weakness and spasticity of the lower limbs. HSP 14 is specifically caused by mutations in the SPG14 gene.

Pathophysiology:
- HSP 14 involves a genetic mutation that affects the normal functioning of motor neurons.
- These mutations lead to defects in proteins essential for mitochondrial function, axonal transport, or myelin integrity.
- The primary pathological feature is the degeneration of the corticospinal tracts, responsible for conveying movement-related information from the brain to the spinal cord.
- This degeneration results in the progressive spasticity and weakness of the lower limbs.
Carrier Status: Hereditary spastic paraplegia 14 (HSP 14) is linked to mutations in the SPG14 gene. Carrier status refers to an individual who has one mutated copy of the gene but does not typically show symptoms of the disease. The inheritance pattern for HSP 14 is autosomal recessive, meaning that two copies of the mutated gene (one from each parent) are necessary for an individual to express the disease phenotype. Therefore, a carrier has one normal gene and one mutated gene and usually will not exhibit symptoms of HSP 14 but can pass the mutated gene to offspring.
Mechanism: Hereditary Spastic Paraplegia 14 (HSP14) is a form of hereditary spastic paraplegia, a group of genetic disorders characterized by progressive weakness and spasticity of the lower limbs. HSP14 is linked to mutations in the SPG14 gene (also known as SPG14/PLP1).

**Mechanism:**
HSP14 is caused by mutations in the SPG14 gene, which encodes the protein spastin. Spastin is involved in the regulation of microtubule dynamics, which are crucial for intracellular transport and the maintenance of neuronal cell structure and function. Mutations in this gene lead to defects in these processes, particularly affecting long motor neurons that extend to the lower limbs, resulting in the characteristic spasticity and weakness.

**Molecular Mechanisms:**
At the molecular level, the SPG14 gene mutations lead to the production of defective spastin proteins. These defective proteins fail to properly sever microtubules, a key step in the cellular process of maintaining the cytoskeleton's dynamic nature. Additionally, the accumulation of improperly regulated microtubules affects axonal transport, leading to the degeneration of long axons. This axonal degeneration predominantly impacts corticospinal motor neurons, causing the progressive motor dysfunction seen in HSP14.

Understanding these molecular mechanisms is crucial for developing targeted therapies to mitigate or reverse the effects of SPG14-related hereditary spastic paraplegia.
Treatment: Hereditary Spastic Paraplegia 14 (HSP 14) currently has no cure. Treatment primarily focuses on managing symptoms and improving quality of life. Approaches may include:

1. **Physical Therapy:** To improve strength, flexibility, and mobility.
2. **Medications:** Such as antispastic drugs to reduce muscle stiffness and spasms.
3. **Occupational Therapy:** To assist with daily activities.
4. **Assistive Devices:** Walkers, canes, or wheelchairs as needed.
5. **Surgical Interventions:** In rare cases, to address severe contractures or deformities.

Consultation with a neurologist and a multidisciplinary team is essential for personalized care.
Compassionate Use Treatment: Hereditary Spastic Paraplegia 14 (HSP 14) is a rare genetic disorder characterized by progressive spasticity and weakness of the lower limbs. For HSP 14 and similar conditions, most treatments are aimed at managing symptoms rather than providing a cure.

1. **Compassionate Use Treatment**: This involves using investigational drugs outside of clinical trials for patients with serious or life-threatening conditions when no comparable or satisfactory alternative therapies are available. Patients or caregivers may need to work closely with their healthcare provider and the drug manufacturer to access these treatments.

2. **Off-label Treatments**: These are medications approved for other conditions but used for HSP 14 based on limited evidence, anecdotal reports, or theoretical benefits. Some off-label medications that might be considered include:
- **Baclofen** or **Tizanidine**: Muscle relaxants to reduce spasticity.
- **Botulinum Toxin Injections**: To help control muscle overactivity and spasticity.
- **Anticonvulsants** like **Gabapentin** or **Pregabalin**: May be used to manage neuropathic pain.

3. **Experimental Treatments**: These include therapies currently under investigation in clinical trials:
- **Gene Therapy**: Research is ongoing to determine if gene therapy could correct the underlying genetic defects causing HSP 14.
- **Stem Cell Therapy**: Some studies are exploring whether stem cell therapy can help repair or replace damaged neurons.
- **New Pharmacological Agents**: Experimental drugs targeting specific pathways involved in the disease mechanism are being studied.

Participation in clinical trials might provide access to these evolving therapies. Patients interested in experimental treatments should consult their healthcare providers about available clinical trials and emerging therapies.
Lifestyle Recommendations: For Hereditary Spastic Paraplegia 14 (HSP 14), lifestyle recommendations generally focus on managing symptoms and improving quality of life. These may include:

1. **Physical Therapy**: Regular physical therapy can help maintain muscle strength, flexibility, and mobility. Stretching and strengthening exercises are often recommended.
2. **Assistive Devices**: Mobility aids such as canes, walkers, or wheelchairs can aid in movement and reduce the risk of falls.
3. **Exercise**: Low-impact exercises such as swimming, cycling, or yoga can improve cardiovascular health and muscle tone without putting too much strain on the body.
4. **Occupational Therapy**: This helps in adapting daily activities and environments to increase independence.
5. **Healthy Diet**: A balanced diet rich in nutrients supports overall health and maintains energy levels.
6. **Hydration**: Ensuring adequate fluid intake can prevent dehydration and support overall bodily functions.
7. **Mental Health Support**: Counseling or support groups may be beneficial for coping with the emotional aspects of the condition.
8. **Regular Medical Check-ups**: Consistent monitoring by a healthcare provider ensures that any complications or changes in symptoms are addressed promptly.

It is essential to consult with healthcare professionals to tailor these recommendations to individual needs.
Medication: Hereditary spastic paraplegia 14 (SPG14) currently has no cure, and treatment mainly focuses on symptom management. Medications to alleviate symptoms may include:

1. Muscle relaxants (e.g., baclofen, tizanidine) to reduce spasticity.
2. Antispasmodic drugs (e.g., botulinum toxin) for muscle spasms.
3. Pain management medications, as necessary.

Each patient's treatment plan should be tailored by a healthcare professional to address specific symptoms and improve quality of life.
Repurposable Drugs: Hereditary Spastic Paraplegia 14 (HSP 14) is a neurodegenerative disorder characterized by progressive weakness and spasticity of the lower limbs. Currently, treatments primarily focus on symptom management rather than altering disease progression.

Potential repurposable drugs include:
1. **Baclofen**: Used for muscle spasticity.
2. **Tizanidine**: Another muscle relaxant that can help with spasticity.
3. **Gabapentin**: Often used for neuropathic pain and may alleviate spasticity.
4. **Dantrolene**: Reduces muscle spasticity by directly acting on the muscle.
5. **Botulinum toxin injections**: Can be used for localized spasticity.

These medications address symptoms and do not cure the underlying genetic cause of the disease. Always consult a healthcare provider for personalized medical advice.
Metabolites: In the context of Hereditary Spastic Paraplegia 14 (HSP14), there is currently limited specific information on metabolites directly linked to this variant of the disease. Hereditary Spastic Paraplegia (HSP) encompasses a group of genetic disorders characterized primarily by progressive spasticity and weakness of the lower limbs. HSP14 specifically is caused by mutations in the SPG14 gene. Altered metabolites are not well-characterized for this subtype, and ongoing research may provide further insights into any metabolomic changes associated with HSP14.
Nutraceuticals: For Hereditary Spastic Paraplegia 14 (HSP 14), there are currently no established nutraceuticals specifically proven to prevent, treat, or cure the condition. Management primarily focuses on symptomatic relief and supportive care, such as physical therapy, medications for muscle stiffness, and orthopedic interventions. Research on potential benefits of various compounds is ongoing, but there is no concrete evidence at this point for specific nutraceuticals.
Peptides: Peptides:

Hereditary Spastic Paraplegia 14 (HSP 14) is caused by mutations in the Spastin gene (SPG14 on chromosome 3), which encodes a protein called spastin. Spastin interacts with microtubules and plays a key role in microtubule severing. Altered peptides or protein fragments resulting from the mutated gene may disrupt normal cellular functions related to axonal transport in neurons.

Nan (not a number):

HSP 14 does not directly relate to the term "nan," which is typically used in computing and mathematics to represent a value that is undefined or unrepresentable. It is unrelated to the clinical or molecular aspects of the disease.